Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by ... ( FORT LEE N.J. Oct. 25 /- Neurologix I...)

HOME >> MEDICINE >> TECHNOLOGY

Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix

Date:10/25/2010

FORT LEE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX) today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.In the study, reduced levels of the p11 protein in the nucleus accumbens (NAcc) of the brain were associated with depressive behaviors in mice. An AAV vector (adeno-associated virus, a disabled, non-pathogenic virus) was used to deliver the p11 gene back into the NAcc of mice who were lacking the p11 protein, reversing the depressive behavior and returning the animals to normal function.

The study also examined samples of brain tissue from a group of deceased human patients, half of whom had severe depression. It was found that there were significantly reduced levels of p11 in the NAcc of depressed patients compared to those without depression. This further highlights the importance of this research in providing a new avenue for future treatment of this widespread disorder.

Neurologix holds the exclusive license to a patent for p11 gene therapy in the treatment of psychiatric conditions, including depression, from Cornell University for and on behalf of the Joan & Sanford I. Weill Medical College. Neurologix scientific co-founder Michael G. Kaplitt, MD, PhD, is co-inventor on the patent, and is the senior author of the research paper.

"The publication of this important research validates our decision to secure the license for developing p11 gene therapy for eventual use in people with
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

Post Your Comments:

(Date:12/4/2013)... CAMBRIDGE, Mass. , Dec. 4, 2013 /PRNewswire/ ... a launchpad for life-sciences startups, announced that Life ... instruments representing the latest platforms developed by the ... Technologies will also provide training and service support ... "Life Technologies has a strong ...

(Date:12/3/2013)... Dec. 3, 2013 Kewaunee Scientific Corporation (Nasdaq: ... its second quarter ended October 31, 2013. ... $0.28 per diluted share, as compared to net earnings ... second quarter last year. A favorable product mix, lower ... previously reported buyout of the minority interest in its ...

(Date:12/3/2013)... -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC ... based on its expertise in opioid antagonists, has ... trial with the National Institute on Drug Abuse ... supports Lightlake,s intranasal delivery of naloxone as a ... Initial data from the study shows that Lightlake,s ...

Breaking Medicine Technology:LabCentral Signs New Agreement in Support of Life-Sciences Startups 2 LabCentral Signs New Agreement in Support of Life-Sciences Startups 3 Kewaunee Scientific Reports Results for Second Quarter 2 Kewaunee Scientific Reports Results for Second Quarter 3 Kewaunee Scientific Reports Results for Second Quarter 4 Kewaunee Scientific Reports Results for Second Quarter 5 Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment 2 Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment 3

[0] LabCentral Signs New Agreement in Support of Life-Sciences Startups [0] Kewaunee Scientific Reports Results for Second Quarter [0] Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment

... BRUNSWICK, N.J., Jan. 13, 2012 Savient Pharmaceuticals, Inc. (Nasdaq: ... David Veitch as President of Savient Europe, effective January ... the European Union across marketing, sales, market access and ... industry experience. Mr. Veitch will report directly to Mr. ...

... (Nasdaq: CRDC ) today announced the suspension ... MicroCutter XPRESS™ 30 due to a small subset of ... in thicker tissue. The company has isolated the underlying ... been no serious adverse events and all patients have ...

Cached Medicine Technology:Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe 2 Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe 3 Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe 4 Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe 5 Cardica Provides Update on MicroCutter™ Program 2 Cardica Provides Update on MicroCutter™ Program 3 Cardica Provides Update on MicroCutter™ Program 4

Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe Cardica Provides Update on MicroCutter™ Program

(Date:12/4/2013)... Sublime Beauty® offers a downloadable Christmas Gift Guide ... gift ideas to help shoppers. , The fun Stocking ... has lots of ideas for men and women. , The ... can benefit from free and fast shipping. , December ... Supersaver shipping (purchases over $35), and December 21st is the ...

(Date:12/4/2013)... Medical researchers point to developmental factors, specifically the ... explanation for why children get less sleep as ... that social ties, including relationships with peers and ... sleep patterns among adolescents. , "My study found ... development as predictors of teen sleep behaviors," said ...

(Date:12/4/2013)... new guideline released Thursday by the Infectious Diseases Society ... immune systems are especially vulnerable to illness and should ... guideline, entitled "Clinical Practice Guideline for the Vaccination of ... MD, director of the pediatric infectious diseases at Cohen ... Park, NY, and professor of pediatrics at the Hofstra ...

(Date:12/4/2013)... (PRWEB) December 04, 2013 Eczema or ... the skin. Beat Eczema is the latest book that ... and easily within a few weeks. The book ... atopic dermatitis such as causes, signs and symptoms, treatment ... people will discover a list of healthy foods that ...

(Date:12/4/2013)... 2013 Angular cheilitis is inflammation of ... of cheilitis (inflammation of the lips). Angular Cheilitis-Free Forever ... get rid of their angular cheilitis naturally and quickly ... information about this disease such as signs and symptoms, ... Jason White, alternative medical practitioner, health consultant, and nutrition ...

Breaking Medicine News(10 mins):Health News:Social ties more important than biology when it comes to teen sleep problems 2 Health News:Social ties more important than biology when it comes to teen sleep problems 3 Health News:Pediatric infectious disease chief authors new vaccination guideline for immunocompromised patients 2 Health News:The Beat Eczema Guide Reveals to People Natural and Safe Remedies for Eliminating Their Atopic Dermatitis Easily Within Weeks – Vinamy 2 Health News:The Beat Eczema Guide Reveals to People Natural and Safe Remedies for Eliminating Their Atopic Dermatitis Easily Within Weeks – Vinamy 3 Health News:The Angular Cheilitis-Free Forever Book Teaches People How To Prevent Or Remove Their Skin Diseases Naturally And Effortlessly – Vinamy 2 Health News:The Angular Cheilitis-Free Forever Book Teaches People How To Prevent Or Remove Their Skin Diseases Naturally And Effortlessly – Vinamy 3

[0] Stocking Stuffer Ideas from Sublime Beauty® Including a Short Jazzy Video; Find Great Gifts and Benefit From Holiday Sales [0] Social ties more important than biology when it comes to teen sleep problems [0] Pediatric infectious disease chief authors new vaccination guideline for immunocompromised patients [0] The Beat Eczema Guide Reveals to People Natural and Safe Remedies for Eliminating Their Atopic Dermatitis Easily Within Weeks – Vinamy [0] The Angular Cheilitis-Free Forever Book Teaches People How To Prevent Or Remove Their Skin Diseases Naturally And Effortlessly – Vinamy

... examination is its limited capacity to determine the ... between benign and malignant lymph nodes and focal ... difficult and frequently requires EUS-guided fine needle aspiration ... been presented as a novel technique that can ...

... disease benefit in the long term from non-drug treatment ... mainly due to the fact that convincing studies are ... indications of a benefit, but also of harm. This ... Institute for Quality and Efficiency in Health Care, Cologne, ...

... Conn., April 15 Rib-X Pharmaceuticals, Inc. ("Rib-X" or ... and development of novel antibiotics for the treatment of ... antibiotic patent in China. The State Intellectual Property ... Chinese Patent Number ZL 2004 8 0021883.9 to Rib-X. ...

... and St. Michael,s Hospital Present New Findings on Nuts ... DAVIS, Calif., April 15 While nuts have been shown ... which will be presented this week at the Experimental Biology ... also play an important role in the management of diabetes. ...

... 15.9 Percent (GAAP EPS Growth of 53.3 Percent) -- Confirms Double-Digit ... Percent - , , ABBOTT PARK, Ill., ... results for the first quarter ended March 31, 2009., ... per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, ...

... Inc., a clinical technology organization providing image management ... and clinical data registries, announced today that it ... Vice President, Business Development. In his new role ... managing all M2S sales efforts and overseeing the ...

Can EUS elastography help distinguish benign from malignant tissue?Non-drug treatment of Alzheimer's disease: Long-term benefit not proven Rib-X Granted Key Antibiotic Patent in China New Research Shows Tree Nuts May Play an Important Role in the Health of People With Diabetes Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 Leading Clinical Technology Organization M2S Inc. Announces the Appointment of Jeffrey Yablon as Senior Vice President, Business Development

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Secobarbital Se, Serum Scopolamine, Serum or Plasma Schlichter Test